Unicycive Therapeutics, Inc.
UNCY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001766140
No open-market purchases or sales by Unicycive Therapeutics, Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $54.6M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Unicycive Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 15 | 16 | +1 |
| Shares | 1.07M | 14.2M | +13.1M (+1,220.9%) |
| Value | $1.38M | $12.2M | +$10.8M (+787.4%) |
New holders (6)
Institutions that held Unicycive Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ra Capital Management, L.P. | 3,470,688 | $2.98M | 0.06% |
| Vivo Capital, LLC | 3,470,152 | $2.98M | 0.37% |
| BVF Inc | 3,413,563 | $2.94M | 0.08% |
| Beacon Pointe Advisors, LLC | 11,861 | $10.2K | 0.00% |
| Two Sigma Securities, LLC | 11,165 | $9.60K | 0.00% |
| Virtu Financial LLC | 10,994 | $9.00K | 0.00% |
Sold out (5)
Institutions that held Unicycive Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Ground Swell Capital, LLC | 20,001 | $25.6K |
| Two Sigma Advisers, LP | 15,200 | $19.5K |
| Centiva Capital, LP | 15,186 | $19.4K |
| XTX Topco Ltd | 14,461 | $18.5K |
| Oxbow Advisors, LLC | 11,861 | $15.2K |